Which medication should be monitored for signs of toxicity, especially lung congestion?

Prepare for the HESI Dosage Calculations Exam. Engage with challenging flashcards and multiple-choice questions, each equipped with explanations. Get set for your exam success!

Daunorubicin is an anthracycline chemotherapy agent that is used primarily in the treatment of certain types of cancer, particularly leukemia. One of the well-known side effects of daunorubicin and similar medications is cardiotoxicity, which can lead to congestive heart failure. This heart-related issue can manifest as pulmonary congestion, where fluid accumulates in the lungs, resulting in symptoms such as shortness of breath, cough, and decreased oxygen saturation.

Monitoring for signs of toxicity is crucial when administering daunorubicin, particularly lung congestion, because early recognition can help manage and mitigate severe complications. Other toxicities associated with daunorubicin include myelosuppression, which can lead to increased risk of infections and bleeding, but the emphasis on monitoring pulmonary congestion highlights the importance of cardiovascular health when using this medication.

In contrast, the other medications listed – cyclophosphamide, levothyroxine, and desmopressin – do not primarily carry risks of lung congestion as a sign of toxicity. Cyclophosphamide can lead to other toxic effects, such as hemorrhagic cystitis, levothyroxine may cause hyperthyroid symptoms if overdosed, and desmopressin's potential side effects are more

Subscribe

Get the latest from Examzify

You can unsubscribe at any time. Read our privacy policy